University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk)

Vogiatzoglou, Anna, Mulligan, Angela A, Bhaniani, Amit, Lentjes, Marleen A.H, McTaggart, Alison, Luben, Robert N., Heiss, Christian, Kelm, Malte, Merx, Marc W., Spencer, Jeremy P.E , Schroeter, Hagen, Khaw, Kay-Tee and Kuhnle, Gunter G.C. (2015) Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk) Free Radical Biology and Medicine, 84. pp. 1-10.

Full text not available from this repository.

Abstract

Dietary intervention studies suggest that flavan-3-ol intake can improve vascular function and reduce the risk of cardiovascular diseases (CVD). However, results from prospective studies failed to show a consistent beneficial effect. Associations between flavan-3-ol intake and CVD risk in the Norfolk arm of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) were investigated. Data were available from 24,885 (11,252 men; 13,633 women) participants, recruited between 1993 and 1997 into the EPIC-Norfolk study. Flavan-3-ol intake was assessed using 7-day food diaries and the FLAVIOLA Flavanol Food Composition database. Missing data for plasma cholesterol and vitamin C were imputed using multiple imputation. Associations between flavan-3-ol intake and blood pressure at baseline were determined using linear regression models. Associations with CVD risk were estimated using Cox regression analyses. Median intake of total flavan-3-ols was 1034 mg/d (range: 0–8531 mg/d) for men and 970 mg/d (0–6695 mg/d) for women, median intake of flavan-3-ol monomers was 233 mg/d (0–3248 mg/d) for men and 217 (0–2712 mg/d) for women. There were no consistent associations between flavan-3-ol monomer intake and baseline systolic and diastolic blood pressure (BP). After 286,147 person-years of follow-up, there were 8463 cardiovascular events and 1987 CVD related deaths; no consistent association between flavan-3-ol intake and CVD risk (HR 0.93, 95% CI: 0.87; 1.00; Q1 vs Q5) or mortality was observed (HR 0.93, 95% CI: 0.84; 1.04). Flavan-3-ol intake in EPIC-Norfolk is not sufficient to achieve a statistically significant reduction in CVD risk.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
NameEmailORCID
Vogiatzoglou, Anna
Mulligan, Angela A
Bhaniani, Amit
Lentjes, Marleen A.H
McTaggart, Alison
Luben, Robert N.
Heiss, Christianc.heiss@surrey.ac.uk
Kelm, Malte
Merx, Marc W.
Spencer, Jeremy P.E
Schroeter, Hagen
Khaw, Kay-Tee
Kuhnle, Gunter G.C.
Date : 17 March 2015
DOI : 10.1016/j.freeradbiomed.2015.03.005
Uncontrolled Keywords : Flavan-3-ols; Cardio-vascular diseases; Nutritional epidemiology; EPIC Norfolk
Depositing User : Melanie Hughes
Date Deposited : 15 Aug 2018 14:26
Last Modified : 15 Aug 2018 14:26
URI: http://epubs.surrey.ac.uk/id/eprint/848954

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800